Seattle Genetics Offers Data Supporting Antibody-Drug Conjugate, Novel Immuno-Oncology Programs at AACR Meeting

Seattle Genetics, Inc. (NASDAQ: SGEN) today highlighted multiple data presentations that support several of the company's antibody-drug ...